The English language literature has been reviewed in order to evaluate the present knowledge on morphine's metabolism and pharmacokinetics in children. The majority of preterm neonates are capable of glucuronidating morphine, but birth weight, gestational and postnatal age influence the glucuronidation capability. Term neonates, infants, and children are able to produce morphine glucuronides. For the reported pharmacokinetics parameters a metaanalysis was made; volume of distribution, estimated to be 2.8±2.6 l·kg −1 , seems to be regardless of age, while half-life and clearance were found to be related to age. Half-life was estimated to be 9.0±3.4 h in pre-term neonates, 6.5±2.8 h in term neonates aged 0-57 days, and 2.0±1.8 h for infants and children aged 11 days to 15 years. Clearance was estimated to be 2.2±0.7 ml·min −1 ·kg −1 for preterm neonates, 8.1±3.2 ml·min −1 ·kg −1 in term neonates aged 0-57 days, and 23.6±8.5 ml·min −1 ·kg −1 in infants and children more than 11 days old.
Introduction
feel pain' or 'children do not remember pain and therefore do not experience pain in the same way as Different studies have found that children adults do, consequently they do not need analgesic postoperatively did not get analgesic treatment to the treatment to the same extent as adults do'. These same extent as adults, and that children often beliefs have been proven wrong (7) (8) (9) . Other experienced postoperative pain (1) (2) (3) (4) (5) (6) . The reasons for misconceptions are, that it is unsafe to administer the undertreatment of pain in children were partly due opioids to children, and that children often suffer to the persistence of old myths such as 'small infants respiratory depression following administration of have an immature nervous system and are unable to morphine. The aim of this review is to evaluate the present knowledge of the metabolism and and children, and in this way contribute to the basis on Table 1 The percentage of the number of preterm neonates studied from whom M3G and M6G have been detected from either plasma or urine samples.
Author Sample (n) M3G detected (%) M6G detected (%)
Choonara et al. (12) 9 SS * 100 56 Bhat et al. (16) 13 SD † 38 23 Chay, Duffy, Walker (17) 4 SS 100 0 Hartley et al. (18) 10 SS 100 100 Hartley et al. (19) 23 SS 100 100 * SS = sampling in steady state; † SD = sampling after single dose administration. The neonates were born at 24-37 gestational week, weighed 580-2260 g and were 0-12 postnatal days old.
which clinical decisions on morphine usage in children et al. had a group of neonates, 46%, from whom it are made. The findings of this review are presented in was impossible to detect either M3G or M6G (16) . This two articles; part one discusses the pharmacokinetics could be because they studied morphine metabolism of morphine, and part two the clinical use of morphine.
after a single dose of morphine while the other groups English language literature has been identified by used steady-state measurements. Another diverging Medline searches, and additional publications from factor is the study population as Bhat et al. studied cited references. To obtain the most accurate data only neonates that were younger and lighter than those original articles have been included, hence published of the other studies. It is controversial whether abstracts are omitted.
gestational age, birth weight and postnatal age influence the glucuronidation capacity (16, 17, 19) , but gestational age and birth weight influence the
Metabolism and excretion
maturity and the size of the liver. Hartley et al. found a weak, but significant correlation between Glucuronidation is the main metabolic route of glucuronidation capability and gestational age (19). morphine with morphine-3-glucuronide, (M3G), and
Another metabolic pathway of morphine is morphine-6-glucuronide (M6G) being the most sulphation; this pathway has only been briefly abundant metabolites. The glucuronidation process studied. Morphine has been found to be conjugated is mainly located in the liver. The formed to morphine-3-sulphate in premature neonates and glucuronides are excreted by the kidneys, and children, but the available findings signify that impaired renal function leads to accumulation of sulphation is a minor metabolic pathway of morphine M3G and M6G (10, 11) .
and that sulphation is diminished after the neonatal It has been suggested that the glucuronidation period (21). Preliminary results have supported these pathway is present, but immature at birth and findings, and indicated that the glucuronide/ continues to develop after the neonatal period, and sulphate ratio in infants is 1.5 (13, 22) . Unfortunately that the M3G and M6G pathways develop in a parallel no follow-up investigations have been reported. manner (12, 13) . It is well established that term
The ratio of M6G/M3G increases with decreasing neonates, infants and children are capable of birth weight (13) indicating that the formation of metabolizing morphine to M3G and M6G (10,12,14, the analgesic active metabolite, M6G, increases with 15). In preterm neonates the development of the decreasing birth weight. This can, however, probably glucuronidation pathway has been studied by several not explain the longer duration of action after a single groups (12, (16) (17) (18) (19) who have reported diverging dose of morphine in neonates, since the ratios of results concerning the presence of M3G and M6G M3G/morphine and M6G/morphine in both plasma (Table 1 ). In four of the studies M3G was detected and urine are lower in neonates than in children (12, in either plasma or urine samples from all the 13), signifying that neonates have a lower metabolic neonates (12, (17) (18) (19) and Chay et al. detected M6G in capacity than older children. Thus the longer effect only a part of the neonates producing M3G; possibly due to the sensitivity of the assay (12, 17) . Only Bhat of a single dose of morphine seen in neonates can most probably be ascribed to the lower metabolic pharmacokinetic values (17, 24, 26) and even a triexponential model has been suggested (27). capacity and thereby the lower elimination rate of morphine in neonates.
One study has been concerned with the distribution of morphine into specified tissue. Following long It seems that renal excretion of unchanged morphine is more profound in neonates than in term infusion the cerebrospinal fluid (CSF):plasma ratio was estimated to be 0.52-1.0 (28). It was adults. In adults renal clearance accounts for approximately 10% of the total body clearance (25) , suggested that CSF morphine concentration is approximately equivalent to the concentration of while in preterm infants 3-15% of a morphine dose was excreted as unchanged morphine (16) and in term unbound morphine in plasma, assuming the protein binding of morphine to be 30%, but no definite neonates 16-80% of the infused dose (24) . Estimated renal clearance accounts for 19% of the total body relationship between morphine concentrations in plasma and CSF was established. The assumption clearance in term neonates younger than three months, and for 13% in older infants (13) . As renal that protein binding in children is similar to that in adults seems to be an overestimation as mean protein function develops rapidly during the first days of life due to change from maternal to neonatal renal binding has been reported to be 18-22% in preterm and term neonates, and infants up to the age of 2.5 function, postnatal age may be important for the excretion of unchanged morphine and metabolites.
years (13, 20) and 20-35% in adults (23) . Because protein binding is relatively low in both populations, the difference in protein binding between neonates
Pharmacokinetic parameters
and infants, and adults will probably make the discrepancy in free morphine plasma concentration A number of groups have studied the too small to be of any clinical relevance, keeping in pharmacokinetic behaviour of morphine after mind the individual variation in morphine kinetics. administration in neonates, infants and children.
The reported mean values for volume of The pharmacokinetic parameters of morphine distribution are shown in Figure 1 . There is investigated more extensively include distribution, uniformity between the values irrespective of age of half-life and clearance. The studies identified are the neonates and children studied; meta-analysis listed chronologically according to gestational and yields a mean value for volume of distribution of 2.8 postnatal age in the fact that they studied children following cardiac this has been indicated with a mark at the x-axis. surgery and therefore children with an altered Studies including only one or two children are not cardiovascular status, who could have a distribution included. To evaluate a possible correlation between that differs from the rest of the children studied (29) . studies, meta-analysis based on reported mean
Reported values of volume of distribution from values, standard deviations, and number of children studies that were not eligible for meta-analysis, all studied was performed. The obtained pooled correspond well to those included in the analysis, estimates for volume of distribution, half-life and i.e. to 2.8±2.6 l·kg −1 . clearance are listed in Table 3 .
Distribution
Half-life Elimination is almost always described by a single The distribution of morphine has been described by a bi-exponential function composed of a rapid initial elimination rate, but it has been suggested that the elimination phase is ended by a long terminal halfdistribution phase followed by a more slow elimination phase (12, 20, 25) . However, onelife of 24.8±4.6 hours (30) . This high value is probably not only a result of elimination, but also of compartment and noncompartment assumptions have also been used in the calculation of redistribution from peripheral tissue into plasma. 
Figure 1 Figure 3
Reported mean values and standard deviations for the clearance Reported mean values and standard deviations for the volume of distribution of morphine in preterm and term neonates, infants, of morphine in preterm and term neonates, infants, and children. The reference numbers refer to the studies listed in Table 2 , and and children. The reference numbers refer to the studies listed in Table 2 , and are ordered according to the age of the children are ordered according to the age of the children studied. studied. Χ Premature neonates; Ε neonates, infants and children.
pharmacokinetic assumptions and calculations, results from most of the studies could be included in the pooled estimate for half-life. Three studies reported results that differed significantly; these different results can be explained by dissimilarities in study populations (29, 31) and the occurrence of one child with very altered pharmacokinetics (30) .
Reported values of morphine half-life from studies that were not eligible for meta-analysis, do all correspond well with those included in the analysis, i.e. to the pooled values for morphine's half-life in preterm neonates, term neonates, and infants and children more than 11 days old. There are diverging reports concerning the independent of gestational and postnatal age (17,30),
The reference numbers refer to the studies listed in Table 2 , and while others have correlated half-life to gestational are ordered according to the age of the children studied.
age (26, 31) or postnatal age (22).
In Figure 2 are shown reported half-lives of Clearance morphine. The tendency that half-life decreases with increasing age can be confirmed by meta-analysis. Clearance is the pharmacokinetic parameter that has been studied most intensively (Figure 3 ). For preterm neonates the pooled estimate was 9.0±3.4 h, for term neonates aged 0-57 days As expected, clearance increases with age, but it is not possible to derive as consistant a pattern for 6.5±2.8 h, and for infants and children aged 11 days to 15 years 2.0±1.8 h.
the development of clearance as for half-life, and reported mean clearance values from less of the Despite differences in study design, indication for morphine usage, analytical procedures and children studied can be included in the pooled T. KART ET AL.
estimate. Some of the differences can be explained and desulphation processes in neonates and infants by disparity in study populations and sampling are more rapid than the glucuronidation and methods, but the differences might also reflect a very sulphation reactions, and this is the reason why it is dynamic pattern for the development of clearance only possible to detect limited amounts of especially rate, which is not easily divided into three groups M6G and the sulphate glucuronides. One possible according to age, as done in the meta-analysis. For metabolic pathway of morphine in neonates and preterm neonates the pooled estimate for clearance infants that has not been studied is the is 2.2±0.7 ml·min , and the good correlation to adult studies found no correlation between clearance and values indicates that the distribution of morphine gestational or postnatal age (17, 30) , while other might be considered similar throughout the neonatal investigators found a significant correlation between period, infancy, childhood and adult life. In contrast clearance and gestational age (20,26,31); Bhat et al. even to this, half-life decreases and clearance increases with reported morphine clearance to increase with age. Based on the meta-analysis, it appears that gestational age at a rate of 0.9 ml·kg
preterm neonates have to be regarded as a separate Also a correlation between clearance and both group with regard to half-life and clearance, while gestational age and birth weight has been observed (32).
the age for distinguishing between term neonates and This presentation of the pharmacokinetics of infants is more uncertain. It has also been revealed that morphine has revealed great intervariability, and to some neonates even from the age of two weeks have illustrate this with some examples, Chay et al. in a half-life resembling adult half-life, while others do neonates observed a three-fold variation in morphine not reach adult value before the age of two months. half-life and a seven-fold variation in clearance (17) .
Regarding clearance, all studies which included Millar et al. registered two-fold variation in morphine neonates younger than one week estimated mean steady state concentrations among children receiving clearance to be below 9 ml·min
, which is lower morphine infusions with equivalent infusion rates than adult clearance, and by the age of two months (33). Intrapatient variability has also been reported. almost all studies, have estimated clearance to more Over a ten day period Nahata et al. found a two-fold than 20 ml·min −1 ·kg −1 , corresponding to adult variation in steady state morphine plasma clearance. Hence, it seems reasonable to consider, that concentration in one patient, who received a constant infants from the age of two months have a half-life and hourly dose of morphine (34). a clearance rate of morphine similar to adults, but it is necessary to keep in mind that in some babies the Discussion neonatal period may be as short as two weeks.
The clinical state of the child probably influences This review shows that neonates and infants have a the metabolism of morphine and hence the metabolism of morphine that is different from adults. pharmacokinetic parameters. The documentation for It seems that the majority of preterm neonates are this is limited, but clearance has been reported to be capable of conjugating morphine to either M3G, M6G reduced during surgery (27), and the cardiac state or both, and that birth-weight may be correlated with of the child may influence the elimination rate of the glucuronidation capability, but that other factors morphine (29) . such as postnatal age also are important. It has been This discussion of the pharmacokinetic parameters stated that, the glucuronidation capacity of the liver of morphine in neonates, infants, and children will in term neonates and infants is present, but immature be the basis for calculations of recommended dosages at birth, and develops during the neonatal period. It could also be, however, that the deglucuronidation for morphine in Part 2.
